Novo Nordisk Aktie - NOV

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

54,83

Gebot

54,69

Fragen

54,96

Volumen

259.472

52,90 Tagesbereich 55,78

9,6779 52-Wochen-Bereich 139,88

Marktkapitalisierung

246,516B

Handelsende

55,12

Handelsbeginn

55,66

Letzte Trade

54.96

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

200.990

Ausgegebene Aktien

4.496.011.436

Dividendenrendite

155.22%

Kurs-Gewinn-Verhältnis

2,77

Gewinn pro Aktie (EPS)

22,46

Erlöse

290,4B

Nettogewinn

100,99B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.novonordisk.com

Hauptsitz

Bagsvaerd, Dnk

Gegründet

Novo Nordisk is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker NOV. The last closing price for Novo Nordisk was 55,12 €. Over the last year, Novo Nordisk shares have traded in a share price range of 9,6779 € to 139,88 €.

Novo Nordisk currently has 4.496.011.436 shares in issue. The market capitalisation of Novo Nordisk is 247,82 € billion. Novo Nordisk has a price to earnings ratio (PE ratio) of 2.77.

Novo Nordisk announces changes in Executive Management

Novo Nordisk announces changes in Executive Management Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in...

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025...

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral...

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Resolutions from the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General...

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist Guangdong...

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial...

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Trading in Novo Nordisk shares by board...

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors Phase...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 6 February 2025 — This...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.25	0.458043239282	54.58	55.78	52.9	187904	55.17	DE
4	-9.67	-14.992248062	64.5	65.2	52.51	247945	59.0835168	DE
12	-27.76	-33.6118174113	82.59	90.49	52.51	200990	70.84562931	DE
26	-50.87	-48.1267738884	105.7	110	9.6778999	165912	78.86650639	DE
52	-63.15	-53.5260213596	117.98	139.88	9.6778999	110297	90.32585855	DE
156	-36.87	-40.2071973828	91.7	139.88	9.6778999	94406	93.96754565	DE
260	-36.87	-40.2071973828	91.7	139.88	9.6778999	94406	93.96754565	DE

NOV - Frequently Asked Questions (FAQ)

What is the current Novo Nordisk share price?

The current share price of Novo Nordisk is 54,83 €

How many Novo Nordisk shares are in issue?

Novo Nordisk has 4.496.011.436 shares in issue

What is the market cap of Novo Nordisk?

The market capitalisation of Novo Nordisk is EUR 247,82B

What is the 1 year trading range for Novo Nordisk share price?

Novo Nordisk has traded in the range of 9,6779 € to 139,88 € during the past year

What is the PE ratio of Novo Nordisk?

The price to earnings ratio of Novo Nordisk is 2,77

What is the cash to sales ratio of Novo Nordisk?

The cash to sales ratio of Novo Nordisk is 0,96

What is the reporting currency for Novo Nordisk?

Novo Nordisk reports financial results in DKK

What is the latest annual turnover for Novo Nordisk?

The latest annual turnover of Novo Nordisk is DKK 290,4B

What is the latest annual profit for Novo Nordisk?

The latest annual profit of Novo Nordisk is DKK 100,99B

What is the registered address of Novo Nordisk?

The registered address for Novo Nordisk is NOVO ALLE, BAGSVAERD, DK-2880

What is the Novo Nordisk website address?

The website address for Novo Nordisk is www.novonordisk.com

Which industry sector does Novo Nordisk operate in?

Novo Nordisk operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WW6Ww International Inc	0,3468 € (169,88%)	144,1k
OYM1Odyssey Marine Exploration Inc	1,39 € (82,89%)	120,38k
VW5Cannabist Company Holdings Inc	0,0643 € (78,61%)	153,41k
Z620Trillion Energy International Inc	0,0307 € (48,31%)	103,45k
K8DWellfield Technologies Inc	0,0142 € (47,92%)	500
A07Avance Gas Holding Ltd	0,27 € (-46,80%)	1,26M
3SHShunfeng International Clean Energy Limited	0,0014 € (-36,36%)	3k
SQRSaia Inc.	216,00 € (-30,77%)	528
L7C2Windfall Geotek Inc	0,008 € (-30,43%)	32,29k
3PJ1Golden Dory Resourses	0,02 € (-25,93%)	40k
DMLSayona Mining Limited	0,0113 € (4,63%)	2,52M
11LCanopy Growth Corporation	1,222 € (-6,86%)	2,31M
PF8European Lithium Limited	0,0314 € (3,29%)	2,18M
D7GNel ASA	0,1982 € (-1,49%)	2,15M
3CPXiaomi Corporation	5,459 € (-1,83%)	1,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novo Nordisk (NOV)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Novo Nordisk

NOV Neueste Nachrichten

Novo Nordisk announces changes in Executive Management

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Resolutions from the Annual General Meeting of Novo Nordisk A/S

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

NOV - Frequently Asked Questions (FAQ)

Beweger

NOV Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novo Nordisk (NOV) Börsenkurse

Novo Nordisk (NOV)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Novo Nordisk

NOV Neueste Nachrichten

Novo Nordisk announces changes in Executive Management

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Resolutions from the Annual General Meeting of Novo Nordisk A/S

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

NOV - Frequently Asked Questions (FAQ)

Beweger

NOV Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen